U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H56NO5PS
Molecular Weight 525.765
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Ilmofosine

SMILES

CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C

InChI

InChIKey=ODEDPKNSRBCSDO-UHFFFAOYSA-N
InChI=1S/C26H56NO5PS/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22-34-25-26(23-30-5)24-32-33(28,29)31-21-20-27(2,3)4/h26H,6-25H2,1-5H3

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/14977826 | https://www.ncbi.nlm.nih.gov/pubmed/19839267 | https://www.ncbi.nlm.nih.gov/pubmed/11772309 | https://www.ncbi.nlm.nih.gov/pubmed/8135843

Ilmofosine (1-hexadecylthio; 2-methoxyethyl-racglycero-3-phosphocholine) is a synthetic 1-S-thioether alkyl lysophospholipid derivative with potential antineoplastic activity. In extensive preclinical evaluation against tumor cell lines and in the human tumor colony-forming assay, Ilmofosine was cytotoxic against both leukemias and solid tumors. Ilmofosine was effective against many tumor types, including ovary, non-small cell lung, kidney, and melanoma. Ilmofosine exhibited competitive inhibition of protein kinase C activity with respect to phosphatidyl-serine and inhibited the enzyme activated by diolein.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.56 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
30.2 μg/mL
450 mg/m² 1 times / week single, intravenous
dose: 450 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ILMOFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
33.91 μg/mL
650 mg/m² 1 times / week multiple, intravenous
dose: 650 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ILMOFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
109.2 μg × h/mL
450 mg/m² 1 times / week single, intravenous
dose: 450 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ILMOFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
148.26 μg × h/mL
650 mg/m² 1 times / week multiple, intravenous
dose: 650 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ILMOFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
37.15 h
450 mg/m² 1 times / week single, intravenous
dose: 450 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ILMOFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
41.65 h
650 mg/m² 1 times / week multiple, intravenous
dose: 650 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ILMOFOSINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.
1996
Patents

Patents

Sample Use Guides

300 mg/m2 per day for five days.
Route of Administration: Intravenous
Promastigotes of L. donovani (1 107 parasites/mL) were cultivated in TC-199 medium supplemented with 20 % of IFCS, at which previously 38 μM of the edelfosine or miltefosine or ilmofosine had been added. After five days, the parasites were spun to 2,000 g for 10 minutes, and the pellet was washed in PBS and fixed for two hours in cacodylate buffer (0.05 M, pH 7.4) containing p-formaldehyde and glutaraldehyde (in equal shares) 2 % (v/v). Then, it was transferred for eight hours in 0.1 M cacodylate buffer with 2 % of glutaraldehyde. Postfixation was carried out for two hours with 2 % of osmium tetroxide (p/v) and potassium ferrocyanide 2 % (p/v). Once the fixation was completed, the staining of the blocks was performed with 1 % of uranyl acetate solution (p/v) for 30 minutes. Then, the blocks were dehydrated in a growing series of alcohols. The infiltration was carried out in resin Spurr for one hour and the polymerization was done in 12 hours
Name Type Language
Ilmofosine
INN   MART.   USAN  
USAN   INN  
Official Name English
BM-41.440
Code English
(±)-Ilmofosine
Common Name English
3,5-Dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide
Systematic Name English
ilmofosine [INN]
Common Name English
Ilmofosine [MART.]
Common Name English
Ilmofosine [USAN]
Common Name English
BM 41.440
Code English
Choline hydroxide, (±)-3-(hexadecylthio)-2-(methoxymethyl)propyl hydrogen phosphate, inner salt
Common Name English
BM-41440
Code English
THIO ALP
Brand Name English
3,5-Dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide, (+/-)-
Common Name English
1-Hexadecylmercapto-2-methoxymethyl-3-propyl phosphoric acid monocholine ester
Common Name English
Code System Code Type Description
NCI_THESAURUS
C166877
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
ChEMBL
CHEMBL28930
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
PUBCHEM
55008
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
INN
5941
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
FDA UNII
5ZZK34MC3V
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
CAS
89315-55-9
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
SUPERSEDED
SMS_ID
100000083704
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
CAS
83519-04-4
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID2049008
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
USAN
DD-2
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY
EVMPD
SUB08132MIG
Created by admin on Fri Dec 15 18:36:40 GMT 2023 , Edited by admin on Fri Dec 15 18:36:40 GMT 2023
PRIMARY